A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors.

@inproceedings{Kunz2010API,
  title={A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors.},
  author={Peter Kunz and Thauming Kuo and Jacob M. Zahn and Holger Kaiser and Jeffrey A Norton and Brendan C. Visser and Teri A. Longacre and James M. Ford and Raymond R. Balise and George A. Fisher},
  year={2010}
}
4104 Background: Neuroendocrine tumors (NETs) are a rare and heterogeneous class of neoplasms. They frequently metastasize to the liver and have a unique hypervascular appearance, making this class of tumors an interesting target for angiogenesis inhibition. Methods: Patients (pts) with biopsy proven metastatic or unresectable neuroendocrine tumors received bevacizumab 7.5 mg/kg IV and oxaliplatin 130 mg/m2 IV on day 1 and capecitabine 850 mg/m2 twice daily by mouth on days 1-14 on a 21-day… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 28 CITATIONS

Biologics in gastrointestinal and pancreatic neuroendocrine tumors.

  • Journal of gastrointestinal oncology
  • 2017
VIEW 1 EXCERPT
CITES BACKGROUND

Chemotherapy in NETs: When and how

Anna Angelousi, Gregory Kaltsas, Anna Koumarianou, Martin O. Weickert, Ashley B. Grossman
  • Reviews in Endocrine and Metabolic Disorders
  • 2017

Systemic Therapies for Advanced Gastrointestinal Carcinoid Tumors.

  • Hematology/oncology clinics of North America
  • 2016
VIEW 1 EXCERPT
CITES BACKGROUND

Systemic Therapies for Advanced Pancreatic Neuroendocrine Tumors.

  • Hematology/oncology clinics of North America
  • 2016
VIEW 1 EXCERPT
CITES BACKGROUND